Blog
RSS FeedPosted by Michael Wonder on 05 Nov 2017
Obamacare vs. the saboteurs
4 November 2017 - Despite the best efforts of the Trump administration and Republicans in Congress to destroy the Affordable ...
Posted by Michael Wonder on 05 Nov 2017
Trevena announces submission of new drug application to U.S. FDA for Olinvo (oliceridine injection)
2 November 2017 - Filing supported by positive Phase 3 APOLLO and ATHENA studies. ...
Posted by Michael Wonder on 05 Nov 2017
Progenics Pharmaceuticals completes submission of NDA for Azedra (iobenguane I 131) in pheochromocytoma and paraganglioma
2 November 2017 - Progenics Pharmaceuticals announced today that it has completed the rolling submission of its new drug application ...
Posted by Michael Wonder on 05 Nov 2017
Trump administration strikes policy that supporters say helped lower drug prices
2 November 2017 - The Trump administration on Thursday boldly reversed an Obama-era policy that supporters said had helped lower ...
Posted by Michael Wonder on 05 Nov 2017
Bausch & Lomb and Nicox announce FDA approval of Vyzulta (latanoprostene bunod ophthalmic solution), 0.024%
2 November 2017 - Valeant Pharmaceuticals' wholly owned subsidiary, Bausch & Lomb and Nicox today announced that the U.S. FDA has ...
Posted by Michael Wonder on 03 Nov 2017
GSK’s investigational BCMA antibody-drug conjugate receives breakthrough therapy designation from US FDA for relapsed and refractory multiple myeloma
2 November 2017 - GlaxoSmithKline today announced that it has received breakthrough therapy designation from the U.S. FDA for GSK2857916 monotherapy ...
Posted by Michael Wonder on 03 Nov 2017
What level of health spending is “affordable”?
2 November 2017 - Among the much-repeated words woven into the US debate on national health policy are “affordability” and “sustainability.” ...
Posted by Michael Wonder on 03 Nov 2017
Challenges in measuring the affordability of US health care
2 November 2017 - Emanuel and colleagues propose an affordability Index to measure the ability of the average US household ...
Posted by Michael Wonder on 02 Nov 2017
FDA grants rare paediatric disease designation to ArQule's miransertib (ARQ 092) for the treatment of Proteus syndrome
1 November 2017 - ArQule today announced that the U.S. FDA has granted rare paediatric disease designation to miransertib (ARQ ...
Posted by Michael Wonder on 02 Nov 2017
FDA grants fast track designation to Visterra’s VIS410 for treatment of hospitalised patients with influenza A
1 November 2017 - Company plans to initiate Phase 2b clinical trial in early 2018. ...
Posted by Michael Wonder on 01 Nov 2017
Trump talks tough but little action seen on drug prices
1 November 2017 - President Trump blasted the pharmaceutical industry for “getting away with murder” with steep drug prices during ...
Posted by Michael Wonder on 01 Nov 2017
U.S. states allege broad generic drug price-fixing collusion
1 November 2017 - A large group of U.S. states accused key players in the generic drug industry of a broad ...
Posted by Michael Wonder on 01 Nov 2017
GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Completes Rolling New Drug Application Submission to U.S. Food and Drug Administration for Epidiolex (cannabidiol) in the treatment of Lennox-Gastaut syndrome and Dravet syndrome
30 October 2017 - GW Pharmaceuticals today announced it has completed the rolling submission of a new drug application to ...
Posted by Michael Wonder on 01 Nov 2017
Bayer announces BAY94-9027 biologics license application accepted by U.S. Food & Drug Administration
30 October 2017 - The U.S. FDA has accepted Bayer's biologics license application filing for BAY94-9027, an extended half-life site-specifically PEGylated ...
Posted by Michael Wonder on 01 Nov 2017
Geron announces fast track designation granted to imetelstat for lower risk myelodysplastic syndromes
31 October 2017 - Expanded part 1 of IMerge is open for patient enrolment. ...